ArticlePediatric nephrology (Berlin, Germany)2013
Atypical HUS: time to take stock of current guidelines and outcome measures?
Article in Pediatric nephrology (Berlin, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Atypical hemolytic uremic syndrome: a clinical conundrum.Pediatric nephrology (Berlin, Germany) · 2016Article
- Article
- Success of eculizumab in the treatment of atypical hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2015Article
- Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.Journal of clinical immunology · 2015Article
- Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency.Pediatric nephrology (Berlin, Germany) · 2014Article
- Successful treatment of DEAP-HUS with eculizumab.Pediatric nephrology (Berlin, Germany) · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
European guidelines for the assessment and management of atypical HUS were written in 2009. Since then our understanding of this group of diseases has advanced. Evidence is emerging that eculizumab, a monoclonal antibody inhibiting C5 activation, is effective, and potentially superior to current treatment with plasmapheresis. The evidence base for the benefits of plasmapheresis consists of case series and small reports. Before we embark on a change of management policy it is vital that we set up a system for genetic diagnosis, standardised protocols and a means to collect predetermined outcome measures, so that we do not make the same mistakes with assessment of the effectiveness of eculizumab as we did for plasmapheresis.
Indexed as
Identifiers
23389238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.